Real-life Effectiveness of Vortioxetine in Patients With Major Depressive Disorder: Non-interventional, Multi-national, Prospective Cohort Study to Assess Real-life Effectiveness of Vortioxetine
Real-life Effectiveness of Vortioxetine in Patients With Major Depressive Disorder: Non-interventional, Multi-national, Prospective Cohort Study to Assess Real-life Effectiveness of Vortioxetine
Worldwide Major Depressive Disorder (MDD) has significant negative personal, societal and economic consequences.
Vortioxetine (Brintellix®) is a new antidepressant authorized since 2013. Despite evidence generated from clinical trials which demonstrate that vortioxetine is an efficacious, well-tolerated antidepressant, there is a need to determine the effectiveness of vortioxetine in real life routine practice.
The study aim is to examine the real-life effectiveness of vortioxetine on functioning, depressive symptom relief, cognition and quality of life.
This is an observational, multi-national, study in patients with MDD initiating treatment with vortioxetine. Information will be collected by the physician, from the patient and their medical record at three time points - baseline, week 12 and week 24 (end of follow-up). This study will be conducted in six countries. In total 2,100 patients are planned for enrolment.
Inclusion Criteria:
Exclusion Criteria:
Saint Charles, Missouri 63304, United States
London, Ontario N6C0A7, Canada
Point Claire, Quebec H9R4S3, Canada
Nice, 06002, France
Toulon, 83000, France
Albese Con Cassano, Milano 22032, Italy
Roma, Rome 00163, Italy
Milan, 20157, Italy
Roma, 00185, Italy
Rome, 00168, Italy